Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

Dean Follmann, Meagan P. O’Brien, Jonathan Fintzi, Michael P. Fay, David C. Montefiori, Allyson Mateja, Gary Herman, Andrea T. Hooper, K. C. Turner, K.-c. Chan, Eduardo Forleo‐Neto, Flonza Isa, Lindsey R. Baden, Hana M. El Sahly, Holly Janes, Nicole A. Doria‐Rose, Jacqueline M. Miller, Haiyu Zhou, Weiping Dang, David Benkeser, Youyi Fong, Peter B. Gilbert, Mary Marovich, Myron S. CohenNature Communications 2023 · DOI

Abstract

While new vaccines for SARS-CoV-2 are authorized based on neutralizing antibody (nAb) titer against emerging variants of concern, an analogous pathway does not exist for preventative monoclonal antibodies. In this work, nAb titers were assessed as correlates of protection against COVID-19 in the casirivimab + imdevimab monoclonal antibody (mAb) prevention trial (ClinicalTrials.gov #NCT4452318) and in the mRNA-1273 vaccine trial (ClinicalTrials.gov #NCT04470427). In the mAb trial, protective efficacy of 92% (95% confidence interval (CI): 84%, 98%) is associated with a nAb titer of 1000 IU50/ml, with lower efficacy at lower nAb titers. In the vaccine trial, protective efficacies of 93% [95% CI: 91%, 95%] and 97% (95% CI: 95%, 98%) are associated with nAb titers of 100 and 1000 IU50/ml, respectively. These data quantitate a nAb titer correlate of protection for mAbs benchmarked alongside vaccine induced nAb titers and support nAb titer as a surrogate endpoint for authorizing new mAbs.

Introduction

In the rapidly evolving landscape of SARS-CoV-2, regulatory bodies face a significant bottleneck. While new vaccine boosters are frequently authorized based on "immunobridging"—demonstrating they elicit sufficient neutralizing antibodies (nAbs)—preventative monoclonal antibodies (mAbs) have traditionally required slow, expensive clinical endpoint trials to prove efficacy against new variants.

The central question addressed in this research is whether nAb titers can serve as a universal surrogate endpoint for both vaccines and mAbs. To establish this, researchers sought to determine if a specific level of antibodies provides the same level of protection regardless of whether those antibodies were endogenous (induced by vaccination) or exogenous (administered via mAb injection).

Methods and Datasets

The study performed a comparative analysis of data from two major Phase 3 trials:

  1. COV-2069: A prevention trial for the casirivimab + imdevimab mAb combination (n=1,630).
  2. COVE: The primary efficacy trial for the mRNA-1273 (Moderna) vaccine (n=28,281).

Researchers utilized a validated lentivirus-based pseudo-virus neutralization assay to measure nAb titers, standardizing results into International Units (IU50/ml). Pharmacokinetic modeling was employed to predict the specific nAb titer an individual likely possessed at the moment of viral exposure. Proportional hazards models then correlated these predicted titers with the risk of symptomatic COVID-19, focusing on the D614G variant dominant during the trial periods.

Key Results

The analysis revealed a strong correlation between predicted nAb titers and protection in both groups (p < 0.01). At high antibody levels, both modalities performed exceptionally well. Specifically, a nAb titer of 1000 IU50/ml was associated with 92% protective efficacy for the mAb treatment and 97% for the vaccine.

However, a critical divergence appeared at lower antibody levels. While vaccine efficacy remained high even at lower titers (93% at 100 IU50/ml), mAb protection faded significantly faster as titers dropped.

Correlation between predicted nAb titers and protective efficacy for vaccines (VE) and monoclonal antibodies (PE).

Additionally, the study noted differences in antibody persistence. The median half-life of nAb titers was significantly shorter for mAbs (26 days) compared to vaccine-induced antibodies (70 days).

Key Insights: Active vs. Passive Immunity

The most striking insight is the "safety net" provided by vaccination. mAb treatment is a form of passive immunity, providing only the antibodies themselves. In contrast, vaccination induces active immunity, training the immune system to produce not just polyclonal antibodies, but also memory B cells and T cells.

Conceptual model comparing protection mechanisms of vaccination versus monoclonal antibody injection at high and low antibody titers.

The study suggests that at low circulating antibody levels, these "backup" systems—especially T cells—are what maintain high levels of protection against symptomatic disease in vaccinated individuals. This is further supported by the observation of an "anamnestic" (memory-based) surge in antibodies among vaccinated individuals who experienced breakthrough infections, a response largely absent in those with high baseline titers or those receiving passive mAb therapy.

Conclusion and Future Directions

This research provides strong quantitative support for using nAb titers as a correlate of protection, offering a benchmark that could streamline the authorization of future mAb therapies through immunobridging.

Several limitations remain. The data predates the Omicron era; current variants have evolved significant immune evasion, likely raising the absolute titers required for protection. Furthermore, the study focused on systemic (blood) antibodies rather than mucosal immunity in the respiratory tract. Future work should focus on establishing immunobridging protocols for mAbs to ensure that immunocompromised individuals, who often fail to respond to vaccines, can gain rapid access to effective antibody treatments as the virus continues to mutate.

Summary updated

Abstract

While new vaccines for SARS-CoV-2 are authorized based on neutralizing antibody (nAb) titer against emerging variants of concern, an analogous pathway does not exist for preventative monoclonal antibodies. In this work, nAb titers were assessed as correlates of protection against COVID-19 in the casirivimab + imdevimab monoclonal antibody (mAb) prevention trial (ClinicalTrials.gov #NCT4452318) and in the mRNA-1273 vaccine trial (ClinicalTrials.gov #NCT04470427). In the mAb trial, protective efficacy of 92% (95% confidence interval (CI): 84%, 98%) is associated with a nAb titer of 1000 IU50/ml, with lower efficacy at lower nAb titers. In the vaccine trial, protective efficacies of 93% [95% CI: 91%, 95%] and 97% (95% CI: 95%, 98%) are associated with nAb titers of 100 and 1000 IU50/ml, respectively. These data quantitate a nAb titer correlate of protection for mAbs benchmarked alongside vaccine induced nAb titers and support nAb titer as a surrogate endpoint for authorizing new mAbs.
BibTeX
@inproceedings{follmann2023examining,
  author = {Dean Follmann and Meagan P. O’Brien and Jonathan Fintzi and Michael P. Fay and David C. Montefiori and Allyson Mateja and Gary Herman and Andrea T. Hooper and K. C. Turner and K.-C. Chan and Eduardo Forleo‐Neto and Flonza Isa and Lindsey R. Baden and Hana M. El Sahly and Holly Janes and Nicole A. Doria‐Rose and Jacqueline M. Miller and Haiyu Zhou and Weiping Dang and David Benkeser and Youyi Fong and Peter B. Gilbert and Mary Marovich and Myron S. Cohen},
  title = {{Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration}},
  booktitle = {Nature Communications},
  year = {2023},
  doi = {10.1038/s41467-023-39292-w},
}
Figure